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ABSTRACT
Introduction: Insulin analogues have become
increasingly popular despite their greater cost
compared with human insulin. The aim of this study
was to calculate the incremental cost to the National
Health Service (NHS) of prescribing analogue insulin
preparations instead of their human insulin
alternatives.
Methods: Open-source data from the four UK
prescription pricing agencies from 2000 to 2009 were
analysed. Cost was adjusted for inflation and reported
in UK pounds at 2010 prices.
Results: Over the 10-year period, the NHS spent
a total of £2732 million on insulin. The total annual
cost increased from £156 million to £359 million, an
increase of 130%. The annual cost of analogue insulin
increased from £18.2 million (12% of total insulin
cost) to £305 million (85% of total insulin cost),
whereas the cost of human insulin decreased from
£131 million (84% of total insulin cost) to £51 million
(14% of total insulin cost). If it is assumed that all
patients using insulin analogues could have received
human insulin instead, the overall incremental cost of
analogue insulin was £625 million.
Conclusion: Given the high marginal cost of analogue
insulin, adherence to prescribing guidelines
recommending the preferential use of human insulin
would have resulted in considerable financial savings
over the period.
INTRODUCTION
The number of people diagnosed with dia-
betes in the UK has risen to 2.8 million,1e4
with approximately 90% of these having type
2 diabetes.5 Patients with type 1 diabetes
require insulin from diagnosis, whereas those
with type 2 diabetes tend to be switched to
insulin later in the natural history of their
disease.6
Insulin analogues were developed to better
mimic the pharmacokinetic profile of
endogenous insulin, thereby achieving more
optimal onset or duration of action and
simpler dosing regimens.7 8 Since their
launch, the use of insulin analogues has
increased steadily.9 In England, the annual
net ingredient cost (NIC) of analogue insulin
in 2004e2005 was £109.8 million (55% of
total insulin cost), which had risen to £255.2
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ARTICLE SUMMARY
Article focus
- Insulin analogues have become increasingly
popular in recent years.
- Insulin analogues are more costly than their
human insulin alternatives.
- The aim of this cross-sectional study is to
calculate the incremental cost to the National
Health Service (NHS) of prescribing analogue
insulin preparations instead of their human
insulin alternatives.
Key messages
- If all dispensations for analogue insulin between
2000 and 2009 had used a human insulin
alternative, the NHS would have saved an
estimated £625 million.
- Given the high marginal cost of analogue insulin,
adherence to prescribing guidelines recom-
mending the preferential use of human insulin
would have resulted in considerable financial
savings over the period.
Strengths and limitations of this study
- The calculation of the incremental cost of
analogue insulin was based on an assumption
that the same volume of insulin would be
prescribed if patients were switched from
analogue to human insulin.
- Some data were missing from the Welsh
Prescription Cost Analysis (PCA) and had to be
estimated using PCAs from alternative countries
in alternative years. This cost was adjusted for
inflation and was unlikely to have impacted on
the estimates as a whole as the net ingredient
cost and volume of these products was small.
- PCA only includes information on how much
insulin was dispensed and not how many
prescriptions were collected by patients with
type 2 diabetes.
- There is no definitive figure on how many
patients with type 2 diabetes could have received
human insulin instead of analogue insulin.
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million (85.3% of total insulin cost) by 2009e2010.9
A similar trend was observed in the early 1980s when
human insulin was introduced and the use of animal
insulin decreased rapidly.10 This occurred despite a lack
of evidence to indicate any benefits of human over
animal insulin.7 10 The Institute for Quality and Effi-
ciency in Healthcare (IQWiG) in Germany has ques-
tioned whether the benefits of insulin analogues are
sufficient to outweigh their increased cost.11 12 In the
UK, the National Institute for Heath and Clinical
Excellence (NICE) recommends the use of human
neutral protamine Hagedorn insulin (NPH) as first-line
therapy. Insulin glargine is only recommended in
specific circumstances, and not as first-line therapy.13
Accordingly, the aim of this study was to characterise
the pattern of insulin prescriptions dispensed between
2000 and 2009, inclusive, for the whole of the UK, and to
evaluate the marginal financial cost to the National
Health Service (NHS) of using analogue insulin instead
of its equivalent human insulin preparation. This anal-
ysis formed the basis of the cost-saving estimates recently
presented by the BMJ and Channel 4 News.14
METHODS
Open-source data from the four prescription pricing
agencies for England,15 Northern Ireland,16 Scotland17
and Wales18 were used in this study. The Prescription
Cost Analyses (PCAs) for England, Northern Ireland
and Wales describe the quantity and NIC of all NHS
prescriptions dispensed in primary care in the constit-
uent country. The NIC refers to the cost of the drug
before any discounts, and does not include any
dispensing costs or fees.19 The PCA for Scotland spec-
ifies gross ingredient cost, which is equivalent to NIC in
the PCAs for England, Northern Ireland and Wales.17
The PCAs for the four countries from 2000 to 2009 were
combined. Data were grouped into insulin types
according to their molecular origin (analogue, human-
sequence and animal-sequence) and also into indi-
vidual insulin types (insulin soluble, insulin isophane,
insulin zinc suspension mixed, insulin zinc suspension
crystalline, biphasic isophane insulin, protamine zinc
insulin, insulin aspart, insulin lispro, insulin detemir,
insulin glargine, biphasic insulin aspart, biphasic
insulin lispro and insulin glulisine). For the Welsh data
from 2000 to 2004, it was necessary to calculate the
quantity of each type of insulin dispensed from the NIC
per unit quantity from the PCAs for England, Scotland
or Northern Ireland, since the Welsh PCA data did not
include this information until 2005. If the drug name in
the PCA did not specify a presentation, that is a phial,
a pre-filled pen or a cartridge, then it was assumed to be
a phial.
All costs were adjusted for inflation, and they are
reported in UK pounds at 2010 prices using the gross
domestic product deflator published by HM Treasury.20
The incremental cost of analogue insulin was calculated
by summing the NIC of analogue insulin and then
subtracting the cost of dispensing the same volume of
insulin of human origin.
The incremental cost of analogue insulin was also
calculated by assuming that if patients prescribed
analogue insulin had alternatively received human
insulin, they would still have received the same presen-
tation that is, a phial, a prefilled pen or a cartridge for
a reusable pen device, since patients and clinicians
favour the ease-of-administration offered by pen
devices.21 22 Using data from a previous analysis of all
prescribing costs for diabetes throughout the UK,23 we
were further able to estimate the relative volumes of
analogue and human insulin prescribed by the type of
diabetes.
RESULTS
Net ingredient cost of insulin in the UK, 2000e2009
Over the 10-year period, the NHS spent a total of £2732
million on insulin prescriptions. Prescriptions for
analogue insulin accounted for £1629 million (59%),
human insulin £1056 million (39%) and animal insulin
£47.2 million (2%).
The total annual cost of insulin rose from £156 million
in 2000 to £359 million in 2009, a 130% increase (figure
1). In 2000, the annual cost of analogue insulin was
£18.2 million, which represented only 12% of total
insulin cost, while the cost of human insulin was £131
million or 84% of the total insulin cost. Spending on
analogue insulin increased from £192 million (66% of
total insulin cost) in 2005, by which time all the currently
marketed insulin analogues had been launched, to £305
million (85% of total insulin cost) in 2009. During the
same period, the annual cost of human insulin fell from
£95.3 million (33%) to £51.1 million (14%). The cost of
animal insulin per year also decreased from £7.42
million (5%) in 2000 to just £3.07 million (1%) in 2009.
Incremental cost of analogue insulin in the UK, 2000e2009
The unit cost of each insulin preparation is listed in
table 1. Analogue insulin cost on average £2.31 per
millilitre and was therefore 47% more expensive than
human insulin at £1.57 per millilitre. In 2009, the mean
NIC per millilitre was £1.27 for human insulin and £2.25
for analogue insulin. The NIC per millilitre of human
and analogue insulin peaked in 2003 and 2004, respec-
tively. Compared with 2004 values, the NIC per millilitre
in 2009 had decreased by 27% for human insulin and by
7% for analogue insulin (table 2).
These unit costs were used to estimate the maximum,
annual, incremental cost of dispensing analogue insulin
assuming that all analogue prescriptions dispensed
could have been alternatively prescribed as human
insulin. Assuming 100% conversion, the annual incre-
mental cost of analogue insulin increased from £5.18
million in 2000 to £133 million in 2009 (table 3).
Overall, for the 10-year period, the total incremental cost
of analogue insulin was £625 million at 100% conversion
and £312 million at 50% conversion. Between 2005 and
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2009, the incremental cost of analogue insulin was £538
million at 100% conversion and £269 million at 50%
conversion.
Estimated cost by diabetes type
Patients with type 2 diabetes accounted for an estimated
£86.0 million of NHS expenditure on human and
analogue insulin in 2000, increasing to £229 million
(+166%) in 2009. For type 1 diabetes these values were
£62.7 million and £127 million, respectively (+103%).
Over the entire period, the total cost of insulin
prescribing for type 2 diabetes was £950 million for
insulin analogues and £708 million for human insulin
(see table 4). The incremental cost of analogue insulin
for patients with type 2 diabetes was estimated at £306
million at 100% conversion and £153 million at 50%
conversion.
Incremental cost of analogue insulin in the UK taking insulin
presentation into account, 2000e2009
Human insulin is more likely to be dispensed as a phial
when compared to insulin analogues which are typically
administered using a pen device (table 1). If all those
receiving analogue insulin had been dispensed human
insulin instead but the presentation had remained the
same (ie, a phial, a pen or a pen-fill device), then the
incremental cost of analogue insulin in the UK between
2000 and 2009 would have been £271 million at 50%
conversion and £541 million at 100% conversion,
compared with £625 million at 100% conversion (table
3) if insulin presentation is not take into account.
DISCUSSION
Since their launch, insulin analogues have had an
increasing impact on the amount of resources used to
manage diabetes. The annual inflation-adjusted cost to
the NHS of insulin increased from £156 million in 2000
to £359 million in 2009 (a twofold increase). During the
same period, annual NHS spending on analogue insulin
increased from £18 million (12% of total insulin cost) to
£305 million (85% of total insulin cost), while annual
NHS spending on human insulin fell from £130 million
(84%) to £51.1 million (14%). If all dispensations for
analogue insulin between 2000 and 2009 had used the
equivalent human insulin, we estimate the NHS would
have saved £625 million.
While it has been shown that insulin analogues are
associated with reduced weight gain, less hypoglycaemia
(particularly nocturnal), improved lowering of post-
prandial glucose and improved dosing schedules, most
commentators agree that these benefits are modest in
comparison to human insulin.7 8 24 However, the cost
Table 1 Net ingredient cost (NIC) and volume of analogue and human insulin by presentation for the UK, 2000e2009
Insulin formulation NIC£2010 Volume (ml) Percentage NIC£2010/ml
Analogue insulin £1628566 983 706 275942 £2.31
Pen £705567 792 285 036913 40% £2.48
Penfill £839695 265 362 630874 51% £2.32
Phial £83303 925 58 608155 8% £1.42
Human insulin £1055956 518 671 922946 £1.57
Pen £218790 437 117 962069 18% £1.85
Penfill £645030 389 373 850061 56% £1.73
Phial £192135 692 180 110816 27% £1.07
Figure 1 The total annual cost of
insulin prescriptions for the UK,
2000e2009. NIC, net ingredient
cost.
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effectiveness of analogue insulin is likely to vary
depending on the type of diabetes, the clinical charac-
teristics of the individual patient and the particular type
of analogue insulin. For example, rapid-acting insulin
analogues in patients with type 1 diabetes are likely to be
a cost-effective use of finite healthcare resources.25 In
the NICE guidance for the management of patients with
type 2 diabetes, the use of human insulin is recom-
mended as first-line therapy, and long-acting analogues
such as insulin glargine and premixed insulin are only
recommended in certain specific circumstances.26 The
NICE has determined that insulin glargine borders on
being cost effective at current willingness to pay thresh-
olds in patients with type 1 diabetes but that it is not cost
effective in type 2 diabetes.13 In Germany, the IQWiG
disputes the value of insulin analogues in type 2 dia-
betes.11 12 In addition, the Pharmaceutical Management
Agency (PHARMAC) in New Zealand has approved
insulin glargine but only as second-line therapy and has
only recommended its use in those who are allergic
to conventional insulin or have failed to control their
diabetes with conventional insulin.27 A similar recom-
mendation has been made by the Canadian Agency for
Drugs and Technologies in Health where human insulin
is recommended as first-line therapy and insulin
analogues are only recommended for patients who
experience significant hypoglycaemia.28 The longest trial
comparing insulin glargine with insulin isophane
concluded that there was a similar progression to reti-
nopathy with the two agents but less improvement in
glycated haemoglobin levels for the more expensive
product, insulin glargine (0.2%, p¼0.0053).29 Further-
more, although the period from 1997 to 2007 saw the
introduction of insulin analogues and a general increase
in diabetes-related care, this was not accompanied by an
improvement in glycated haemoglobin levels in patients
with type 2 diabetes treated with insulin.30 There is
currently no systematic means of measuring the other
clinical benefits associated with analogue insulin, such as
rate of symptomatic or nocturnal hypoglycaemia,
making it difficult to judge the real-world cost effective-
ness of these drugs. An analysis of open-source Hospital
Episode Statistics (HES) data shows that growth in
hospital admissions for hypoglycaemia has exceeded
growth in the prescribing of insulin.31
The increase in the use of analogue insulin is likely to
be due in part to successful marketing. Some of the
manufacturers of insulin analogues also provided
professional support to general practitioners at the time
their analogue insulin was marketed, although this was
not conditional on the doctor prescribing their
insulin.14 Insulin analogues were also available in new
devices that may be more appealing to patients and
easier to use than the devices used to administer human
insulin.14 The fact that 40% of analogue insulin was
prescribed as a prefilled pen device compared with just
18% of human insulin supports this suggestion. Finally,
a move to patented insulin products has notable
commercial benefits for manufacturers.
Since the introduction of insulin analogues, some
human insulin products have been withdrawn. Patients
using these products have switched to an alternative
product containing either human insulin or an insulin
analogue. In 2005, Novo Nordisk discontinued Actrapid
penfills and recommended NovoRapid as an alternative
product. At the same time, they also withdrew Insulatard
Flexpen and Monotard from their range of human
insulin.32 Since the withdrawal of Mixtard 30 at the end
of 2010, its 90 000 users will have been changed to an
alternative product. It will be interesting to repeat this
study to assess whether these patients have been switched
to human insulin (the equivalent product is Humulin
M3) or indeed to analogue insulin. The Drug and Ther-
apeutics Bulletin has estimated that if all users of Mixtard
30 were switched to NovoMix 30, it would result in an
increase in cost of £9 million to the NHS in England
alone.33
The increase in the annual inflation-adjusted NHS
cost between 2000 and 2009 can be partly accounted for
Table 3 Incremental cost of analogue insulin in the UK,
2000e2009
Year
Incremental cost
(£2010) (assuming
100% conversion
of analogue to
human insulin)
Incremental cost
(£2010) (assuming
50% conversion
of analogue to
human insulin)
2000 £5 183001 £2 591500
2001 £8 065849 £4 032924
2002 £10 795155 £5 397578
2003 £23 143753 £11 571877
2004 £39 529331 £19 764666
2005 £79 448570 £39 724285
2006 £98 317347 £49 158673
2007 £106139197 £53 069598
2008 £121376170 £60 688085
2009 £132895201 £66 447601
Total £624893574 £312446787
Table 2 Average net ingredient cost (NIC) per millilitre in
the UK, 2000e2009
Year
NIC£2010/ml
for human insulin
NIC£2010/ml
for analogue insulin
2000 £1.60 £2.24
2001 £1.69 £2.24
2002 £1.76 £2.25
2003 £1.75 £2.33
2004 £1.74 £2.41
2005 £1.38 £2.36
2006 £1.37 £2.34
2007 £1.37 £2.27
2008 £1.35 £2.30
2009 £1.27 £2.25
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by the increase in the prevalence of diabetes in the UK
during this time. In 1996, it was estimated that 1.4
million people in the UK had diabetes.34 By 2004, this
figure had risen to 1.8 million35 and to 2.6 million by
2009.36 Patients with type 2 diabetes can be managed
with one or more of diet, oral glucose-lowering medica-
tion or insulin, whereas patients with type 1 diabetes are
dependent on exogenous insulin. However, the esti-
mated volume of analogue and human insulin dispensed
to patients with type 2 diabetes is far greater than for type
1 diabetes. This can be explained by the prevalence of
type 2 and type 1 diabetes in the UK. It has been esti-
mated that approximately 90% of people with diabetes in
the UK have type 2 diabetes. It can be further explained
by the nature of type 2 diabetes, which is characterised by
insulin resistance. Patients with type 2 diabetes are more
likely to be overweight or obese than patients with type 1
diabetes.37 Therefore, those with type 2 diabetes using
insulin often receive higher insulin doses. Furthermore,
results from the United Kingdom Prospective Diabetes
Study (UKPDS) may have influenced the increased
prescribing of insulin to patients with type 2 diabetes so
that lower HbA1c levels could be obtained.38
This study had inherent limitations. The calculation of
the incremental cost of analogue insulin was based on
the assumption that the same volume of insulin would be
prescribed if patients were switched from analogue to
human insulin. The PCA for Wales from 2000 to 2004
did not include the quantity of insulin dispensed which
was necessary to calculate the incremental cost. The
quantity, therefore, had to be calculated from the NIC
per quantity figures from the PCAs for England, Scot-
land and Northern Ireland. However, certain products in
the Welsh PCA were not available for the other regions
for the same year, so figures from the previous years had
to be used and adjusted for inflation. Some drugs were
listed only under their generic name in the Welsh PCA
and so a weighted-average NIC per quantity for the
branded products in the English PCA was used. The
same approach was taken when the drug name descrip-
tion did not specify whether the cartridge size was 1.5 ml
or 3 ml (when these were the only cartridge sizes on the
market). In addition, there were two drug names,
Human Actraphane and Human Protaphane phials,
which had no matches in any of the other PCAs for any
year. These are Novo Nordisk products, which tend to
carry the same cost per unit depending on whether they
are phial, penfill or prefilled pen and which is not
dependent on what type of human insulin is in the
device. Therefore, the NIC per quantity used for these
two products was the NIC per quantity of the other Novo
Nordisk phials. These assumptions were unlikely to have
impacted upon the estimates as a whole, since the NIC
and the volume of these products were small.
Another limitation was that the PCA only tells us how
much of each type of insulin was dispensed; thus, there
was no way of determining how much insulin was
dispensed to patients with type 2 diabetes specifically.
However, it is likely that the level of type 1 diabetes
remained relatively constant over the study period, while
the number of patients with type 2 diabetes is known to
have increased considerably.39
The assumption that all patients using insulin
analogues could be equally well treated with human
insulin is also likely to be unrealistic. Dr Adler, chair of
the NICE guidance committee, has suggested that 90%
of patients with type 2 diabetes could receive human
insulin instead of long-acting insulin analogues, with
around two-thirds of these patients remaining on human
insulin.14 Currently, however, there is no definitive figure
for how many people with diabetes could have received
human insulin instead of analogue insulin. The purpose
of this study was to calculate a monetary value to raise
awareness of the cost implications at a population level
of prescribing analogue insulin instead of human insulin
rather than to suggest an exact percentage of patients
with diabetes who could be equally well treated with
human instead of analogue insulin.
Table 4 Estimated change in net ingredient cost (NIC) and volume of human and analogue insulin prescribed to patients with
type 1 and type 2 diabetes in the UK, 2000e2009
Year
NIC£2010 for
type 1 diabetes
NIC£2010 for
type 2 diabetes
Volume (ml) for type
1 diabetes
Volume (ml) for type
2 diabetes
Total
analogue
Total
human
Total
analogue
Total
human
Total
analogue
Total
human
Total
analogue
Total
human
2000 £11 228382 £51 444334 £6 923103 £79 075 954 5 038092 33 056509 3 050474 48 350233
2001 £17 858968 £55 211316 £14 564748 £92 155 033 8 001813 33 577135 6 443335 53 816755
2002 £25 764159 £57 242261 £24 410582 £98 670 067 11 520222 33 039547 10 827941 55 441680
2003 £45 316250 £49 420126 £47 585514 £94 338 575 19 667109 28 663444 20 145487 53 383153
2004 £65 066374 £40 577834 £76 937127 £87 354 455 27 296077 23 712414 31 672369 49 905829
2005 £82 462748 £28 231889 £109 393916 £67 039 353 35 341564 21 196772 45 841398 47 609677
2006 £97 342547 £21 284207 £140 625903 £55 238 238 42 215106 15 771316 59 651444 40 046916
2007 £105277447 £17 662770 £160 494779 £49 900 346 46 896096 13 048606 70 028562 36 438609
2008 £113178916 £14 924884 £179 215091 £45 134 839 49 542256 11 113432 77 455050 33 486730
2009 £114597696 £12 375736 £190 322726 £38 711 902 51 543528 9 734567 84 098018 30 547933
Total £678093486 £348 375355 £950 473489 £707618 762 297061863 222913742 409 214078 449027514
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At the macroeconomic level, we know that the rise of
insulin analogues has had a substantial financial impact
on the NHS, yet over the same period there has been no
observable clinical benefit to justify that investment. It is
likely that there was and is considerable scope for
financial savings. Most worryingly, the clinical role and
safety of insulin for use in people with type 2 diabetes is
being questioned.40e43
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